Genmab has signed an agreement with Baxter Healthcare Corp. for the sale of its non-plasma-derived antibody manufacturing facility in Brooklyn Park, MN, for $10 million. Baxter acquires the facility, land, and equipment at the site, and will offer employment to the 23 employees currently supporting the facility.
 
"We have delivered on our commitment to execute the sale of the antibody manufacturing facility in the first quarter of this year and are very pleased that Baxter acquired the facility, including the 23 employees who have maintained the facility to such a high standard," said Jan van de Winkel, Ph.D., chief executive officer of Genmab.